Use and cost of branded and generic drugs in patients with coronary heart disease-results from a prospective survey of 1008 patients in two London hospitals

QJM: An International Journal of Medicine

Volumn 102, Issue 12, 2009, Pages 843-849

  Corp, E V ^a   Antoniou, S ^a   Wright, P G ^a   Khachi, H ^a   Vercaeren, S ^a   Wald, D S ^a,b  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; RAMIPRIL; SIMVASTATIN; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; AORTA STENOSIS; ARTICLE; ASTHMA; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MYALGIA; NIGHTMARE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RISK REDUCTION; SEXUAL DYSFUNCTION; UNITED KINGDOM; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ECONOMICS; MIDDLE AGED; MULTICENTER STUDY;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; DRUGS, GENERIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES;

EID: 77950556299     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp127     Document Type: Article

References (24)

1. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121:43-9.
2. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
3. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427.
4. National Institute for Health and Clinical Excellence. Postmyocardial infarction - Secondary prevention in primary and secondary care for patients following a myocardial infarction. May 2007. [http://www.nice.org.uk] Accessed 21 August 2008.
5. Hippisley-Cox J, Coupland C. Effect of combination drugs on all cause mortality in patients with ischaemic heart disease: nested cases-control analysis. BMJ 2005; 330:1059-63.
6. Wald NJ, Law MR. A strategy to reduce cardiovascular events by more than 80%. BMJ 2003; 326:1419-23.
7. DeWilde S, Carey IM, Richards N, Whincup PH, Cook DG. Trends in secondary prevention of ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment. Heart 2008; 94:83-8.
8. Fox DJ, Kibiro M, Eichhöfer J, Curzen NP. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention? Postgrad Med J 2005; 81:401-3.
9. Hiratzka LF, Eagle KA, Liang L, Fonarow GC, LaBresh KA, Peterson ED. Get With the Guidelines Steering Committee. Atherosclerosis secondary prevention performance measures after coronary artery bypass graft surgery compared with percutaneous catheter intervention and non-intervention patients in the Get With the Guidelines database. Circulation 2007; 116(Suppl. 11):1207-12.
10. Sambu N, Wald DS, Seddon M, Simpson IA. Undertreatment of coronary heart disease in patients undergoing coronary artery bypass surgery. Heart 2006; 92:697-8.
11. Winkelmayer WC, Bucsics AE, Schautzer A, Wieninger P, Pogantsch M. Pharmacoeconomics Advisory Council of the Austrian Sickness Funds. Use of recommended medication after myocardial infarction in Austria. Eur J Epidemiol 2008; 23:153-62.
12. Prescription Pricing Authority. NHS electronic drug tariff. October 2008. [http://www.ppa.nhs.uk/edt/October_2008/mindex.htm] Accessed 20 October 2008.
13. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalent of generic and brand-name drugs used in cardiovascular disease. A systematic review and meta-analysis. JAMA 2008; 300:2514-26.
14. National Audit Office. Prescribing costs in Primary Care (May 2007). [http://www.nao.org.uk] Accessed 21 August 2008.
15. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data from one million adults in 61 prospective studies. Lancet 2002; 360:1903-13.
16. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326:1423-7.
17. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-504.
18. Moon JC. Switching statins. BMJ 2006; 332:1344-5.
19. National Prescribing Centre. MeReC monthly (June 2008). [http://www.npc.co.uk] Accessed 3 October 2008.
20. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitorinduced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:169-73.
21. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360:752-60.
22. Scheen AJ, Krzesinski JM. ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events. Rev Med Liege 2008; 63:213-9.
23. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
24. British Cardiovascular Intervention Society: BCIS audit. [http://www.bcis.org.uk/resources/audit] Accessed 3 October 2008.